Gain study: A phase III trial to compare ETC versus EC-TX and ibandronate versus observation in patients with node-positive primary breast cancer.
568 Background: Möbus et al. showed that dd epirubicin (E), paclitaxel (T), cyclophosphamide (C) results in a superior DFS compared to conventionally dosed EC-T in pts with primary breast cancer (PBC) and ≥3 involved lymph nodes (LN). In this study, the dd, dose intensified strategy has been further...
| Publicado en: | Journal of Clinical Oncology Vol. 27; pp. 568 - 569 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
5/21/2009 Supplement Part 1 of 2
|
| Acceso en línea: | Ver este registro en EBSCOhost |